Skip to main content

Table 4 Estimates of the normal tissue complication probabilities according to the various models applied and endpoints considered. Results are shown as averages (with uncertainty expressed as 1 standard deviation) and median value (second line). The p value is relative to the Wilcoxon signed rank paired test

From: Intensity modulated proton therapy compared to volumetric modulated arc therapy in the irradiation of young female patients with hodgkin’s lymphoma. Assessment of risk of toxicity and secondary cancer induction

OrganModelEndpointRAIMPT∆(RA-IMPT)p
LADRRFailure1.41 ± 0.341.28 ± 0.390.13 ± 0.150.001
1.281.16
Left VentricleRRFailure1.26 ± 0.201.13 ± 0.180.13 ± 0.10< 0.001
1.201.02
HeartNTCPDeath (LQ)0.16 ± 0.160.15 ± 0.130.02 ± 0.040.03
0.140.120.01
LungsNTCPPneum LQ0.30 ± 0.370.14 ± 0.200.16 ± 0.21< 0.001
0.170.050.09
NTCPPneum LKB1.98 ± 1.041.34 ± 0.740.64 ± 0.47< 0.001
1.771.090.55
NTCPSymPneum LKB4.61 ± 2.983.19 ± 2.271.42 ± 1.13< 0.001
3.842.361.09
NTCPSymFibr LKB3.26 ± 1.792.75 ± 1.720.51 ± 0.45< 0.001
2.752.220.38
EsophagusNTCPEsophagitis2.61 ± 1.492.47 ± 1.520.15 ± 0.270.04
2.472.350.14
Composite 1NTCP12.92 ± 7.0910.02 ± 5.832.90 ± 2.24< 0.001
11.048.172.24
Composite 2RR2.68 ± 0.512.41 ± 0.550.26 ± 0.22< 0.001
2.462.180.22
  1. RR relative risk, NTCP normal tissue complication probability, Pneum LQ Pneumonitis with Poisson-LQ model, Pneum LKB Pneumonitis with Lyman model, SymPneum LKB Symptomatic or radiographic pneumonitis ≤6 months with Lyman model, SymFibr LKB Symptomatic or radiographic fibrosis > 6 months with Lyman Model